The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...
Morning Overview on MSN
Scientists design opioids that ease pain with fewer dangers
Scientists are racing to redesign how powerful painkillers work, aiming to keep the relief that opioids provide while ...
Prescriptions Rising for a New Non-Opioid Analgesic, but Clinicians Are Still Learning Where It Fits
Prescriptions for the new non-opioid pain medication suzetrigine more than doubled between April and August 2025, according to analysis from Epic Research. The increase indicates a growing interest in ...
The US Food and Drug Administration approved a new kind of painkiller that does not have any risk of addiction or overdose, which are generally associated with opioid medications. The drug, ...
Plans to seek regulatory approval to commence a Phase III trial in the US and Canada VANCOUVER, BC, Jan. 8, 2026 /PRNewswire/ -- Sustained Therapeutics Inc. ("Sustained Therapeutics" or the "Company") ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx (suzetrigine) ...
SAN FRANCISCO--(BUSINESS WIRE)--Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company developing novel, non-opioid pain therapeutics, today announced publication of a multicenter, ...
Kids with broken or sprained limbs don't need oral opioids to treat their pain, according to newly published findings from a ...
The Food and Drug Administration has approved a new pain medication that could take the place of opioids for those experiencing moderate to severe acute pain. The drug is Journavx, or the generic name ...
CHATHAM, NEW JERSEY / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp.
(The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s ...
“Today’s approval is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research said in a statement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback